SCIENCE NEWS Recombination Hotspot Stacks the DNA Deck in Finding a New Diabetes Susceptibility Gene Scientists have identified a novel gene associated with diabetes in mice that is revealing new clues about genomic mechanisms that could underlie type 1 diabetes susceptibility. [Press release from EurekAlert! discussing online prepublication in Genome Research] Gefitinib May Have Chemopreventive Benefits in Pancreatic Cancer Gefitinib may be a promising chemoprevention agent for pancreatic cancer. Strategies to combat pancreatic cancer have focused on earlier and earlier treatments, and this is the first time that a chemoprevention strategy has been tried. [Press release from the American Association for Cancer Research discussing online prepublication in Cancer Prevention Research] Team Discovers Promising Target for New Pancreatic Cancer Treatments The KRAS gene, which is mutated in virtually all pancreatic cancers, triggers cancer cell growth in numerous ways through multiple cell signaling pathways, and scientists have had difficulty determining which one will be the most promising to block. Researchers have now narrowed the focus of this scientific quest to a protein called RGL2. [Press release from the University of North Carolina Lineberger Comprehensive Cancer Center discussing online prepublication in the Journal of Biological Chemistry] Italy Carries Out First Hi-Tech Pancreas Transplant Italian doctors have carried out the world’s first robotically-assisted pancreatic transplant in an operation that could help diabetes sufferers everywhere. [Associated Free Press]
|
|
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) DIABETES A Recombination Hotspot Leads to Sequence Variability within a Novel Gene (AK005651) And Contributes to Type 1 Diabetes Susceptibility Researchers describe the positional cloning of a type 1 diabetes (T1D) susceptibility locus, Idd11 , located on mouse chromosome 4. Sequence analysis of a series of congenic nonobese diabetic (NOD) mouse strains over a critical 6.9-kb interval in these mice and in 25 inbred strains identified several haplotypes, including a unique NOD haplotype, associated with varying levels of T1D susceptibility. [Genome Res] Cyclic GMP Kinase I Modulates Glucagon Release from Pancreatic Alpha Cells Researchers propose that cGMP-dependent protein kinase type I modulates glucagon release by suppression of cytosolic Ca2+ in alpha cells. [Diabetes] Beta Cell Function During Rapamycin Monotherapy in Long-Term Type 1 Diabetes Researchers sought to determine whether immunosuppression therapy can reinstate beta cell function in patients with long-term type 1 diabetes. [Diabetologia] Adenylyl Cyclase 8 Is Central to Glucagon-Like Peptide 1 Signaling and Effects of Chronically Elevated Glucose in Rat and Human Pancreatic Beta Cells Glucose and incretins regulate beta cell function, gene expression and insulin exocytosis via calcium and cAMP. Prolonged exposure to elevated glucose disturbs calcium homeostasis, but little is known about cAMP signaling. Researchers therefore investigated long-term effects of glucose on this pathway with special regard to the incretin glucagon-like peptide 1. [Diabetologia] Associations Between the Intake of Caffeinated and Decaffeinated Coffee and Measures of Insulin Sensitivity and Beta Cell Function In this cross-sectional study, caffeinated coffee was positively related to insulin sensitivity and decaffeinated coffee was favorably related to measures of beta cell function. These results provide pathophysiological insight as to how coffee could impact the risk of type 2 diabetes mellitus. [Diabetologia] BK Channels Affect Glucose Homeostasis and Cell Viability of Murine Pancreatic Beta Cells Ablation or inhibition of BK channels impairs glucose homeostasis and insulin secretion by interfering with beta cell stimulus-secretion coupling. In addition, BK channels are part of a defense mechanism against apoptosis and oxidative stress. [Diabetologia] STAT1 Is a Master Regulator of Pancreatic Beta Cells Apoptosis and Islet Inflammation The present study elucidates the transcriptional networks through which the IFN-gamma/STAT1/IRF-1 axis controls beta cell function/differentiation, demise and islet inflammation. [J Biol Chem] PANCREATIC CANCER The Epidermal Growth Factor Receptor Inhibitor Gefitinib Prevents the Progression of Pancreatic Lesions to Carcinoma in a Conditional LSL-KrasG12D/+ Transgenic Mouse Model The present study highlights the promise of chemoprevention and the potential usefulness of epidermal growth factor receptor inhibitors in individuals at high risk for pancreatic cancer. [Cancer Prev Res] Aberrant Overexpression of the Rgl2 Ral Small GTPase-Specific Guanine Nucleotide Exchange Factor Promotes Pancreatic Cancer Growth Through Ral-Dependent and Ral-Independent Mechanisms Observations support nonredundant roles for RalGEFs in Ras-mediated oncogenesis and a key role for Rgl2 in Ral activation and Ral-independent pancreatic ductal adenocarcinoma growth. [J Biol Chem] Pancreatic Bicarbonate Secretion: A Case for Two Proton Pumps Researchers show that pancreatic ducts express functional gastric and non-gastric H+-K+-ATPases. [J Biol Chem] PHD3 Regulates Differentiation, Tumor Growth and Angiogenesis in Pancreatic Cancer Results indicate essential functions of prolyl hydroxylase-3 (PHD3) in tumor growth, apoptosis and angiogenesis and through hypoxia-inducible factor-1 (HIF-1)-dependent and HIF-1-independent pathways. [Br J Cancer]
|
|
INDUSTRY NEWS Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes Arena Pharmaceuticals, Inc. announced that, following the completion of a Phase I clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010. [Arena Pharmaceuticals, Inc. Press Release] Texas Center for Cancer Nanomedicine Targets Two Tough Cancers A $16-million, five-year grant by the National Cancer Institute’s nanomedicine initiative blends the expertise of five research institutions to focus an array of innovative nanotechnologies on improving the outcome of patients with ovarian or pancreatic cancers. [University of Texas MD Anderson Cancer Center Press Release] Million-Dollar Gift Boosts Joslin Treatment for Children with Diabetes Joslin Diabetes Center has received a $1 million gift that will broaden full access to pediatric clinical services for children with diabetes and their families. Given by the Thomas J. Beatson, Jr. Foundation, the donation will offer major support for the Joslin Pediatric, Adolescent and Young Adult Clinic’s care ambassador program. [Joslin Diabetes Center Press Release] Jefferson Researchers Receive W.W. Smith Charitable Trust Researchers at Jefferson Medical College of Thomas Jefferson University have been awarded a W.W. Smith Charitable Trust medical research grant. This one-year grant awards $100,000 to their group to help support their innovative cancer research, and one of the questions they will address is why African-Americans respond poorly to common chemotherapeutic agents used to treat pancreatic cancer. Another question this grant will address is what genes in cancer cells are regulated upon stressful conditions such as chemotherapeutic treatments. [EurekAlert!] Finding the Missing Markers: University of Utah Team Wins Federal Grant to Develop Pancreatic Cancer Testing Technology Building on advances made in high-speed, high-sensitivity magnetic sensing, a team of University of Utah researchers has been awarded a five-year, $2.3 million federal grant to create a nanotechnology-based platform for the early detection of pancreatic cancer. [Innovation Utah Press Release] KOMBIGLYZE™ XR (Saxagliptin and Metformin HCl Extended-Release) Tablets Approved in the U.S. for the Treatment of Type 2 Diabetes Mellitus in Adults Bristol-Myers Squibb Company and AstraZeneca announced that the U.S. Food and Drug Administration approved KOMBIGLYZE™ XR for the treatment of type 2 diabetes in adults. [Bristol-Myers Squibb Company Press Release]
|
|
EVENTS (Listed by Date) 10th Annual Meeting of the Diabetes Technology Society November 11-13, 2010 Bethesda, United States Select Biosciences 2nd International Forum on Stem Cells (2010 IFSC) November 12-13, 2010 Tianjin, China Australasian Pancreatic Club Annual Meeting November 15-16, 2010 Melbourne, Australia Pharmacology in Stem Cells Research and Regenerative Medicine December 17, 2010 London, United Kingdom Type 2 Diabetes, Insulin Resistance and Metabolic Dysfunction January 12-17, 2011 Dillon, United States Keystone Symposia: Obesity January 12-17, 2011 Keystone, United States 2011 Gastrointestinal Cancers Symposium January 20-22, 2011 San Francisco, United States Epithelial Plasticity and Epithelial to Mesenchymal Transition January 21-26, 2011 Vancouver, Canada 5th Annual Stem Cells and Regenerative Medicine World Congress January 24-25, 2011 San Diego, United States Phacilitate 7th Annual Cell & Gene Therapy Forum 2011 January 24-26, 2011 Washington, DC, United States Early Development for Innovative Diabetes & Metabolic Syndrome Therapeutics Conference January 26-27, 2011 Amsterdam, The Netherlands Joint Conference of the International Association of Pancreatology and the Indian Pancreas Club February 10-13, 2011 Maradu, India United Kingdom National Stem Cell Network 2011 Annual Scientific Conference March 30-April 1, 2011 York, United Kingdom American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 April 2-6, 2011 Orlando, United States Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES Business Manager – Centre for Blood Cell Therapies (Cell Therapies Pty Ltd) Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies) Lab Technologist – Tissue Culture (STEMCELL Technologies) Product Manager – Pluripotent Stem Cells (STEMCELL Technologies) Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost. Visit here to post your career opportunities.
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! |
| |
|